

Alexandra G Fraga

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8152598/publications.pdf>

Version: 2024-02-01

32
papers

1,454
citations

393982

19
h-index

454577

30
g-index

33
all docs

33
docs citations

33
times ranked

2077
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with <i>Mycobacterium tuberculosis</i> . <i>Journal of Experimental Medicine</i> , 2010, 207, 1609-1616.	4.2	230
2	First Cultivation and Characterization of <i>Mycobacterium ulcerans</i> from the Environment. <i>PLoS Neglected Tropical Diseases</i> , 2008, 2, e178.	1.3	175
3	Infection with <i>Mycobacterium ulcerans</i> Induces Persistent Inflammatory Responses in Mice. <i>Infection and Immunity</i> , 2005, 73, 6299-6310.	1.0	92
4	Evidence for an Intramacrophage Growth Phase of <i>Mycobacterium ulcerans</i> . <i>Infection and Immunity</i> , 2007, 75, 977-987.	1.0	91
5	Phage Therapy Is Effective against Infection by <i>Mycobacterium ulcerans</i> in a Murine Footpad Model. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2183.	1.3	91
6	Mycolactone-Mediated Inhibition of Tumor Necrosis Factor Production by Macrophages Infected with <i>Mycobacterium ulcerans</i> Has Implications for the Control of Infection. <i>Infection and Immunity</i> , 2007, 75, 3979-3988.	1.0	88
7	Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis. <i>International Journal of Antimicrobial Agents</i> , 2008, 31, 37-45.	1.1	85
8	Fine-Needle Aspiration, an Efficient Sampling Technique for Bacteriological Diagnosis of Nonulcerative Buruli Ulcer. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1700-1704.	1.8	58
9	Response to Treatment in a Prospective Cohort of Patients with Large Ulcerated Lesions Suspected to Be Buruli Ulcer (<i>Mycobacterium ulcerans</i> Disease). <i>PLoS Neglected Tropical Diseases</i> , 2010, 4, e736.	1.3	53
10	IFN- γ -Dependent Activation of Macrophages during Experimental Infections by <i>Mycobacterium ulcerans</i> Is Impaired by the Toxin Mycolactone. <i>Journal of Immunology</i> , 2010, 184, 947-955.	0.4	50
11	Developments on Drug Delivery Systems for the Treatment of Mycobacterial Infections. <i>Current Topics in Medicinal Chemistry</i> , 2008, 8, 579-591.	1.0	45
12	BCG vaccination-induced long-lasting control of <i>Mycobacterium tuberculosis</i> correlates with the accumulation of a novel population of CD4+IL-17+TNF+IL-2+ T cells. <i>Vaccine</i> , 2015, 33, 85-91.	1.7	42
13	<i>Mycobacterium ulcerans</i> Triggers T-Cell Immunity followed by Local and Regional but Not Systemic Immunosuppression. <i>Infection and Immunity</i> , 2011, 79, 421-430.	1.0	41
14	K2 Capsule Depolymerase Is Highly Stable, Is Refractory to Resistance, and Protects Larvae and Mice from <i>Acinetobacter baumannii</i> Sepsis. <i>Applied and Environmental Microbiology</i> , 2019, 85, .	1.4	38
15	Cellular Immunity Confers Transient Protection in Experimental Buruli Ulcer following BCG or Mycolactone-Negative <i>Mycobacterium ulcerans</i> Vaccination. <i>PLoS ONE</i> , 2012, 7, e33406.	1.1	38
16	Genetic Variation in Autophagy-Related Genes Influences the Risk and Phenotype of Buruli Ulcer. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004671.	1.3	35
17	Proteomic Analysis of the Action of the <i>Mycobacterium ulcerans</i> Toxin Mycolactone: Targeting Host Cells Cytoskeleton and Collagen. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3066.	1.3	27
18	Antimicrobial activity of <i>Mycobacteriophage</i> D29 Lysin B during <i>Mycobacterium ulcerans</i> infection. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007113.	1.3	25

#	ARTICLE	IF	CITATIONS
19	Clinical Epidemiology of Buruli Ulcer from Benin (2005-2013): Effect of Time-Delay to Diagnosis on Clinical Forms and Severe Phenotypes. PLoS Neglected Tropical Diseases, 2015, 9, e0004005.	1.3	23
20	Local and Regional Re-Establishment of Cellular Immunity during Curative Antibiotherapy of Murine Mycobacterium ulcerans Infection. PLoS ONE, 2012, 7, e32740.	1.1	21
21	Spontaneous Healing of Mycobacterium ulcerans Lesions in the Guinea Pig Model. PLoS Neglected Tropical Diseases, 2015, 9, e0004265.	1.3	18
22	New Foci of Buruli Ulcer, Angola and Democratic Republic of Congo. Emerging Infectious Diseases, 2008, 14, 1790-1792.	2.0	17
23	Natural based eumelanin nanoparticles functionalization and preliminary evaluation as carrier for gentamicin. Reactive and Functional Polymers, 2017, 114, 38-48.	2.0	16
24	Corticosteroid-Induced Immunosuppression Ultimately Does Not Compromise the Efficacy of Antibiotherapy in Murine Mycobacterium ulcerans Infection. PLoS Neglected Tropical Diseases, 2012, 6, e1925.	1.3	13
25	Immune-evasion Strategies of Mycobacteria and Their Implications for the Protective Immune Response. Current Issues in Molecular Biology, 2018, 25, 169-198.	1.0	12
26	Preparation and biological evaluation of ethionamide-mesoporous silicon nanoparticles against Mycobacterium tuberculosis. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 403-405.	1.0	11
27	Increasing the potential of cell-penetrating peptides for cancer therapy using a new pentagonal scaffold. European Journal of Pharmacology, 2019, 860, 172554.	1.7	7
28	Individual and clinical variables associated with the risk of Buruli ulcer acquisition: A systematic review and meta-analysis. PLoS Neglected Tropical Diseases, 2020, 14, e0008161.	1.3	4
29	Genetic variants in human BCL2L11 (BIM) are associated with ulcerative forms of Buruli ulcer. Emerging Microbes and Infections, 2021, 10, 223-225.	3.0	4
30	The Immunology of Buruli Ulcer. , 2019, , 135-158.		3
31	Genetics in the Host-Mycobacterium ulcerans interaction. Immunological Reviews, 2021, 301, 222-241.	2.8	0
32	Multiple facets and functions of the toxin mycolactone produced by Mycobacterium ulcerans. , 2022, , 271-290.		0